CPRC

  • February 18, 2022  

    Olaparib Shows Promise for Castrate-Resistant Prostate Cancer Bookmark

    George Lundberg, MD

    This Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.

    .